Monday, October 19, 2015
Darmstadt, Germany-based Merck has re-launched its visual identity. The fundamental revision of the visual appearance—as well as the introduction of new logos for its U.S. businesses EMD Serono, EMD Millipore and EMD Performance Materials—reflects a transformation into a global science and technology company.
Adheron Therapeutics has been acquired by Roche. Adheron is a privately held biotechnology company developing SDP051, a product that disrupts cell adhesion which can potentially be used to treat inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic disease. SDP051 was fully humanized using Abzena’s Composite Human Antibody technology.
Cancer Genetics, a DNA-based cancer diagnostics provider, has received approval from the U.S. bankruptcy court in Delaware to purchase substantially all of the assets of Los Angeles-based Response Genetics Inc. (RGI), a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. CGI also agreed to assume some of RGI’s liabilities. The sale is subject to certain customary closing conditions and is expected to close by Oct. 9.
Teva Pharmaceutical Industries has agreed to acquire Representaciones e Investigaciones Médicas (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a debt-free, cash free set of transactions, for an aggregate of $2.3 billion.
C.R. Bard, a Murray Hill, N.J.-based multinational developer, manufacturer and marketer of medical technologies, has entered into a definitive agreement to acquire Kobayashi Pharmaceutical’s 50% ownership share in Medicon—the Osaka, Japan-based venture that the two companies have operated together since 1972—through a share redemption. The transaction is expected to close in early November, after which Medicon will be a wholly owned subsidiary of the company. The transaction has been approved by each company’s board of directors and is subject to customary closing conditions.